H.C. Wainwright has taken the unusual step of setting a $0 price target for troubled biotech Sarepta Therapeutics ...

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) had a good week, as its shares rose 3.3% to close at US$87.11 following the release of its yearly results. The statutory results were mixed ...

High-rolling investors have positioned themselves bullish on Sarepta Therapeutics (NASDAQ:SRPT), and it's important for retail traders to take note. \This activity came to our attention today ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $106.75, a high estimate of $202.00, and a low estimate of $75.00.

Ratings for Sarepta Therapeutics (NASDAQ:SRPT) were provided by 25 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below provides a snapshot of ...

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a concise ...

Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00.